All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

Conditions : Respiratory Syncytial Virus (RSV) Interventions : Drug: YKYY025 group; Drug: YKYY025 Placebo group Sponsors : Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Not yet…

Read the full article
17h agoen
sciencehealth

You might also wanna read

Phase I trial shows needle-free pan-Sarbecovirus vaccine is safe with modest immune responses

Needle-free intradermal delivery of this novel computationally designed PanSarbeco vaccine was safe and well tolerated. Although immunogenic

journalofinfection.com·1mo ago

Comments

Sign in to join the conversation.

No comments yet. Be the first.